REGISTERED NUMBER:
|
|
|
|
|
|
|
|
|
|
|
Pharma Biotech System Components Limited |
|
Unaudited Financial Statements |
|
for the Year Ended 31 March 2021 |
|
|
|
|
|
REGISTERED NUMBER:
|
|
|
|
|
|
|
|
|
|
|
Pharma Biotech System Components Limited |
|
Unaudited Financial Statements |
|
for the Year Ended 31 March 2021 |
|
|
|
|
|
Pharma Biotech System Components Limited (Registered number: 05144311) |
|
|
|
|
|
|
Contents of the Financial Statements |
for the year ended 31 March 2021 |
|
|
|
|
Page |
|
Company Information | 1 |
|
Balance Sheet | 2 |
|
Notes to the Financial Statements | 4 |
|
Pharma Biotech System Components Limited |
|
Company Information |
for the year ended 31 March 2021 |
|
|
|
|
|
|
|
DIRECTORS: |
|
|
|
|
|
|
|
|
SECRETARY: |
|
|
|
|
|
|
REGISTERED OFFICE: |
|
|
|
|
|
|
|
|
|
|
REGISTERED NUMBER: |
|
|
|
|
|
|
ACCOUNTANTS: |
|
Aireside House |
Aireside Business Centre |
Royd Ings Avenue |
Keighley |
West Yorkshire |
BD21 4BZ |
Pharma Biotech System Components Limited (Registered number: 05144311) |
|
Balance Sheet |
31 March 2021 |
|
31.3.21 | 31.3.20 |
Notes | £ | £ | £ | £ |
FIXED ASSETS |
Intangible assets | 4 |
|
|
Tangible assets | 5 |
|
|
|
|
|
CURRENT ASSETS |
Stocks |
|
|
Debtors | 6 |
|
|
Cash at bank and in hand |
|
|
|
|
CREDITORS |
Amounts falling due within one year | 7 |
|
|
NET CURRENT ASSETS |
|
|
TOTAL ASSETS LESS CURRENT
LIABILITIES |
|
|
|
PROVISIONS FOR LIABILITIES |
|
|
NET ASSETS |
|
|
|
CAPITAL AND RESERVES |
Called up share capital |
|
|
Retained earnings |
|
|
SHAREHOLDERS' FUNDS |
|
|
|
|
|
|
|
The directors acknowledge their responsibilities for: |
(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
Pharma Biotech System Components Limited (Registered number: 05144311) |
|
Balance Sheet - continued |
31 March 2021 |
|
|
|
|
In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered. |
|
The financial statements were approved by the Board of Directors and authorised for issue on
|
|
|
|
|
|
|
|
Pharma Biotech System Components Limited (Registered number: 05144311) |
|
Notes to the Financial Statements |
for the year ended 31 March 2021 |
|
1. | STATUTORY INFORMATION |
|
Pharma Biotech System Components Limited is a
|
|
The presentation currency of the financial statements is the Pound Sterling (£). |
|
|
2. | ACCOUNTING POLICIES |
|
Basis of preparing the financial statements |
|
|
Revenue recognition |
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. |
|
Intangible assets |
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses. |
|
Tangible fixed assets |
|
Plant and machinery | - |
|
Fixtures and fittings | - |
|
Motor vehicles | - |
|
Computer equipment | - |
|
|
Tangible fixed assets held for the company's own use are stated at cost less accumulated depreciation and accumulated impairment losses. |
|
At the balance sheet date, teh company reviews the carrying amount of its tangible fixed assets to determine whether there is any indication that any items have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss, if any. |
|
Stocks |
Stocks are stated at lower of cost and estimated selling price less costs to completed and sell (net realisable value). Costs, which comprises direct production costs, are based on the method most appropriate to the type of inventory class, but usually on a first in first out basis. Overheads are charged to the profit or loss as incurred. Net realisable value is based on the estimated selling price less any estimated completion or selling costs. |
|
When stocks are sold, the carrying amount of those stocks is recognised as an expense in the period in which the related revenue is recognised. The amount of any write down of stocks to net realisable value and all losses of stocks are recognised as an expense in the period in which the write down or loss occurs. The amount of any reversal of any write down of stocks is recognised as a reduction in the amount of stocks recognised as an expenses in the period in which the reversal occurs. |
|
Pharma Biotech System Components Limited (Registered number: 05144311) |
|
Notes to the Financial Statements - continued |
for the year ended 31 March 2021 |
|
2. | ACCOUNTING POLICIES - continued |
Taxation |
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
|
Current or deferred taxation assets and liabilities are not discounted. |
|
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
|
Deferred tax |
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
|
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
|
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
|
Research and development |
Expenditure on research and development is written off in the year in which it is incurred. |
|
|
Foreign currencies |
Transaction in currencies, other than the functional currency of the company, are recorded at the rate of exchange on the date teh transaction occurred. Monetary items denominated in other currencies are translated at the rate prevailing at the end of teh reporting period. All differences are taken to the profit and loss account. Non monetary items that are measured at historic cost in a foreign currency are not retranslated. |
|
Pension costs and other post-retirement benefits |
The company operates a defined contribution pension scheme. During the year the company contributed £197,200 (2020 £54,141). At the year end contributions of £84,162 (2020 £6,398) had not been paid to the scheme. |
|
Revenue recognition |
The company enters into contracts to provide its services. At the year end all contracts that have not been finalised are reviewed and an estimate of the recoverability of these contracts is determined, based on the expected contract value and work completed to date. |
|
3. | EMPLOYEES AND DIRECTORS |
|
The average number of employees during the year was
|
Pharma Biotech System Components Limited (Registered number: 05144311) |
|
Notes to the Financial Statements - continued |
for the year ended 31 March 2021 |
|
4. | INTANGIBLE FIXED ASSETS |
Goodwill |
£ |
COST |
At 1 April 2020 |
and 31 March 2021 |
|
AMORTISATION |
At 1 April 2020 |
and 31 March 2021 |
|
NET BOOK VALUE |
At 31 March 2021 |
|
At 31 March 2020 |
|
|
5. | TANGIBLE FIXED ASSETS |
Plant and |
machinery |
etc |
£ |
COST |
At 1 April 2020 |
|
Additions |
|
Disposals | ( |
) |
At 31 March 2021 |
|
DEPRECIATION |
At 1 April 2020 |
|
Charge for year |
|
Eliminated on disposal | ( |
) |
At 31 March 2021 |
|
NET BOOK VALUE |
At 31 March 2021 |
|
At 31 March 2020 |
|
|
6. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
31.3.21 | 31.3.20 |
£ | £ |
Trade debtors |
|
|
Amounts recoverable on contract |
|
|
Other debtors |
|
|
|
|
Pharma Biotech System Components Limited (Registered number: 05144311) |
|
Notes to the Financial Statements - continued |
for the year ended 31 March 2021 |
|
7. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
31.3.21 | 31.3.20 |
£ | £ |
Trade creditors |
|
|
Taxation and social security |
|
|
Other creditors |
|
|
|
|
|
8. | OTHER FINANCIAL COMMITMENTS |
|
The company has given Cerrig Holdings Limited a fixed and floating charge over all its property and undertaking regarding a loan made to the company's ultimate holding company. |
|
The company has given Takahe Holdings Limited a fixed and floating charge over all its property and undertaking regarding a loan made to the company's ultimate holding company. |